Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoMTA 2 is a second-generation, bioactive bioceramic repair cement designed for endodontic and restorative dental procedures. Developed by Avalon Biomed, it is a powder-gel system used for applications such as pulpotomy, apexification, and as a coronal plug in revascularization. The material is biocompatible and promotes the formation of hydroxyapatite to facilitate sealing and tissue healing. Compared to its predecessor, NeoMTA Plus, NeoMTA 2 features 30% higher radiopacity, an extended handling time, improved wash-out resistance, and a non-tacky consistency. It is specifically formulated to be non-staining, making it suitable for use in the aesthetic zone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NeoMTA 2.